Molecular Formula | C17H23FN2O4 |
Molar Mass | 338.3739232 |
Density | 1.377±0.06 g/cm3(Predicted) |
Boling Point | 456.9±45.0 °C |
pKa | 13.21±0.40(Predicted) |
Storage Condition | Sealed in dry,Room Temperature |
Use | This product is an intermediate of ABT 199. ABT 199 is an effective selective BCL-2 inhibitor, which has strong anti-tumor activity while retaining platelets. Its practical application is to treat chronic lymphocytic leukemia cells and estrogen receptor positive breast cancer. |
ABT-199 (Venetoclax), unlike common cancer drugs, is a new type of drug that treats cancer by attacking an important protein called BCL-2. BCL-2 is one of the earliest discovered members of the cell death regulatory BCL-2 protein family. It is associated with many types of cancer, as well as some mental and autoimmune diseases. In cancer, it is thought to act as a suppressor that can help cancer cells resist cancer treatment drugs.